QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Aims for Greater Precision in Cancer Therapy
VERAXA Biotech (NASDAQ: VRXA) is developing antibody-based cancer therapies designed to improve treatment selectivity and potentially reduce toxicity to healthy tissues. At the center of its strategy is the proprietary BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) platform, which uses two complementary molecules designed to activate cancer-killing activity only when both recognize targets on the same tumor cell. The company is applying this approach to antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), with a particular focus on solid tumors. VERAXA reported promising preclinical findings for its lead BiTAC-TCE program, including selective targeting of cells expressing both intended targets and improved safety alongside comparable…